Park Square is pleased to announce the placement of Lyndal Hesterberg, Ph.D., as Vice President, Development at Freenome. Freenome is a rapidly growing biotechnology startup developing next-generation blood tests for early cancer detection based on the company’s multi-omics platform. The company has raised over $500 million in funding from top-tier investors.

Hesterberg most recently served as Chief Science Officer at Oncocyte, a publicly-traded, commercial stage molecular diagnostics company focused in lung cancer. Previously, he served as Chief Technology Officer at Crescendo Bioscience, which was acquired by Myriad Genetics. Earlier in his career, Hesterberg served in a variety of R&D leadership positions at BaroFold, SomaLogic, BioStar (acquired by Thermo), and Amgen.

Hesterberg received his B.Sc. in Biochemistry from the University of Illinois and his Ph.D. in Biochemistry from St. Louis University. 

This marks the second search that Park Square has conducted for Freenome:

Park Square Executive Search serves companies and institutions that are shaping the world through discovery, innovation and growth. Our clients are leading life sciences and healthcare organizations, technology companies, major research universities, and venture capital and private equity firms, including their portfolio companies. We place board members, chief executive officers, C-suite executives, and academic leaders.